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AbsTrACT
Objective chemokine pathways are co-opted by 
pancreatic adenocarcinoma (PDac) to facilitate myeloid 
cell recruitment from the bone marrow to establish an 
immunosuppressive tumour microenvironment (tMe). 
targeting tumour-associated cXcr2+neutrophils (tan) 
or tumour-associated ccr2+ macrophages (taM) alone 
improves antitumour immunity in preclinical models. 
However, a compensatory influx of an alternative myeloid 
subset may result in a persistent immunosuppressive 
tMe and promote therapeutic resistance. Here, we show 
ccr2 and cXcr2 combined blockade reduces total 
tumour-infiltrating myeloids, promoting a more robust 
antitumour immune response in PDac compared with 
either strategy alone.
Methods Blood, bone marrow and tumours were 
analysed from PDac patients and controls. treatment 
response and correlative studies were performed 
in mice with established orthotopic PDac tumours 
treated with a small molecule ccr2 inhibitor 
(ccr2i) and cXcr2 inhibitor (cXcr2i), alone and in 
combination with chemotherapy.
results a systemic increase in cXcr2+ tan 
correlates with poor prognosis in PDac, and patients 
receiving ccr2i showed increased tumour-infiltrating 
cXcr2+ tan following treatment. in an orthotopic 
PDac model, cXcr2 blockade prevented neutrophil 
mobilisation from the circulation and augmented 
chemotherapeutic efficacy. However, depletion of 
either cXcr2+ tan or ccr2+ taM resulted in a 
compensatory response of the alternative myeloid 
subset, recapitulating human disease. this was 
overcome by combined ccr2i and cXcr2i, which 
augmented antitumour immunity and improved 
response to FOlFirinOX chemotherapy.
Conclusion Dual targeting of ccr2+ taM and 
cXcr2+ tan improves antitumour immunity and 
chemotherapeutic response in PDac compared with 
either strategy alone.
InTrOduCTIOn
Pancreatic adenocarcinoma (PDAC) is the fourth 
leading cause of cancer-related deaths, with 
incidence expected to increase over the coming 
decade.1 2 Despite advances using conventional 
chemotherapy in PDAC, 5-year survival remains 
a dismal 8%, and the immunosuppressive tumour 
microenvironment (TME) remains a significant 
barrier to effective treatment. This fibrotic stromal 
compartment is infiltrated by tumour-associated 
macrophages (TAM) and tumour-associated neutro-
phils (TAN) that are recruited from the bone marrow 
to facilitate PDAC immune evasion.3 4 Thus, ther-
apies disrupting myeloid trafficking represent an 
attractive modality to restore antitumour immunity.
Neutrophils are the most abundant myeloid 
population, and a systemic granulocytic expansion 
has been reported in cancer, with intratumoural 
accumulation of TAN (CD11b+, CD14−, CD15+ 
and CD66b+) correlating with poor prog-
nosis.5 6 CXCR2 and its ligands in the ELR+ chemo-
kine family, including CXCL1, CXCL2, CXCL3, 
CXCL5, CXCL7 and CXCL8, are responsible for 
recruiting neutrophils under normal physiological 
conditions and have been implicated in tumour-me-
diated TAN mobilisation.7 8 Tumour-bearing 
animals also demonstrate a systemic increase in 
TAN (CD11b+, Gr1High, Ly6CLow and Ly6GHigh), 
and targeting TAN has been shown to increase 
tumour-infiltrating lymphocytes (TIL) and improve 
response to checkpoint blockade in preclinical 
studies.9–13
Our previous work found PDAC expression of 
CCL2 results in mobilisation of CCR2+ inflamma-
tory monocytes from the bone marrow to the tumour, 
where they become immunosuppressive TAM.14 A 
dense TAM (CD11b+, CD115+, CD14+, CD15− 
and CD68+) infiltrate has been associated with 
decreased survival in multiple malignancies and 
targeting CCR2+ TAM (CD11b+, Gr1Low, Ly6Glow, 
Ly6CMid and F4/80High) reduces tumour progression 
in murine cancer models.14–18 Based on these find-
ings, we conducted a clinical trial (NCT01413022) 
in patients with non-metastatic PDAC using 
the orally dosed, small molecule CCR2 inhib-
itor (CCR2i) PF-04136309 in combination with 
FOLFIRINOX that demonstrated a favourable 
 o
n
 5 June 2018 by guest. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2017-313738 on 1 December 2017. Downloaded from 
1113nywening tM, et al. Gut 2018;67:1112–1123. doi:10.1136/gutjnl-2017-313738
Pancreas
clinical response rate compared with chemotherapy alone.19 
However, tumour-mediated recruitment of bone marrow-de-
rived cells is an elaborate process, and disruption by immuno-
modulatory therapies is not without a compensatory response. 
Several studies have found that depleting TAM results in a 
compensatory TAN influx, which may contribute to treatment 
failure following CCR2 blockade.20 21 Thus, it remains unclear if 
disrupting a single myeloid subset is the most effective approach 
to targeting the immunosuppressive TME.
Here we report that targeting CCR2+ TAM results in 
a compensatory neutrophil influx in patients with PDAC, 
providing the first reported evidence that immunomodulating 
therapies may result in dynamic myeloid responses at the 
primary tumour, with the potential to limit intended treatment 
efficacy. This phenomenon is recapitulated in tumour-bearing 
animals, and synergistic targeting of both CXCR2+ TAN and 
CCR2+ TAM prevented a compensatory influx of myeloid 
cells, along with evidence of a more robust antitumour immune 
response. These data build on emerging therapies targeting 
bone marrow-derived cells in human cancer and suggests that 
targeting both TAM and TAN collectively may represent the 
optimal therapeutic combination.
MATerIAls And MeThOds
Analysis of preoperative neutrophil to lymphocyte ratio (nlr)
An institutional review board (IRB)-approved, prospectively 
maintained database of PDAC resections (n=561) performed at 
Barnes Jewish Hospital (St. Louis, Missouri, USA) between 1997 
and 2012 was used, and the NLR was calculated by dividing the 
absolute neutrophil and lymphocyte values from routine preop-
erative labs obtained within 30 days prior to the index pancre-
atectomy. Subjects with leucocytosis (>11 000 cells/dL) (n=51), 
without a differential count (n=64) or postoperative death 
within 30 days (n=7) were excluded. The NLR, as a continuous 
variable, was used as the test state and overall survival as the 
control variable in a standard receiver operator curve (ROC) to 
determine the optimal cut-off point for patient stratification.
Collection of blood, bone marrow and tumour from human 
patients
Human studies were conducted with informed consent under 
IRB-approved protocol at Washington University School of 
Medicine. Unfractionated whole blood and bone marrow aspi-
rates were collected from patients with PDAC and healthy 
controls in EDTA vacuum tubes (BD Bioscience) and under-
went red blood cell (RBC) lysis per manufacturer’s instructions 
(BioLegend). Resected tumour or normal pancreas from organ 
donors without malignancy were processed at time of collection. 
Baseline and post-treatment tumour biopsies from a clinical trial 
were processed as previously described.19 Tissue was allocated 
for cryopreservation, fixation or enzymatically digested to create 
a single cell suspension using GentleMACS (Miltenyi).
PdAC tumour tissue microarray (TMA)
A TMA of treatment-naive PDAC tumours was constructed 
from 1 mm punch biopsies of well-demarcated tumours from 
paraffin-embedded tissue blocks by a pathologist. An Aperio 
Scan-Scope XT Slide Scanner (Aperio Technologies) was used 
to acquire 20× images. A previously validated tumour-specific 
nuclear algorithm (IHC-MARK) was used to quantify protein 
expression.14 22 Positive staining was normalised to total tissue 
surface area and the mean intensity or cellular density per cm2 
was used to classify samples into high, mid and low cohorts and 
overall survival following PDAC resection compared (online 
supplementary figure S1).
Animal studies and cell lines
C57BL/6, CCR2−/− (B6.129S4-Ccr2tm1Ifc/J) and Nur77GFP 
(Nur77-GFPCre) mice were purchased from The Jackson 
Laboratory and maintained in a pathogen-free facility under 
an approved animal studies protocol at Washington Univer-
sity School of Medicine (St. Louis, Missouri, USA). Mice 
were observed daily, and survival events were recorded when 
animals lost >15% total body weight or per absolute survival 
event. The murine PDAC cell line KCKO was the kind gift of 
Dr Pinku Mukherjee.23 KPC cells derived from p48-CRE/
LSL-Kras/p53flox/flox mice were provided by Dr David DeNardo. 
All cell lines tested negative for mycoplasma and verified to be 
of C57BL/6J origin using CellCheck Plus (IDEXX BioResearch). 
Mice aged 8–10 weeks were anaesthetised and injected in the 
tail of the pancreas with 2.5×105 cells suspended in a 1:1 PBS 
to Matrigel (Corning) mixture and randomised to treatment 
96 hours following tumour inoculation. The CXCR2 inhibitor 
(CXCR2i) SB225002 (Tocris) was administered intraperitoneally 
(IP) at a dose of 10 mg/kg daily. The CCR2i RS504393 (Tocris) 
was given subcutaneously (SQ) at a dose of 5 mg/kg twice per 
significance of this study
What is already known on this subject?
 ► Bone marrow-derived myeloid cells, including 
tumour-associated neutrophils (TAN) and tumour-
associated macrophages (TAM) are recruited by pancreatic 
adenocarcinoma (PDAC) and facilitate immune evasion.
 ► PDAC production of CCL2 promotes CCR2+ monocyte efflux 
from the bone marrow to the tumour microenvironment, 
where they become immunosuppressive TAM.
 ► Treatment with a small molecule CCR2 inhibitor, in 
combination with FOLFIRINOX, prevented TAM accumulation 
and demonstrated a promising treatment response rate in 
PDAC compared with chemotherapy alone.
 ► The ELR+/CXCR2 chemokine axis has been implicated in 
PDAC-mediated recruitment of TAN, and CXCR2 blockade has 
shown promise in preclinical tumour studies.
What are the new findings?
 ► Treatment with a CCR2 inhibitor results in a compensatory 
influx of CXCR2+ TAN in patients with human PDAC.
 ► A systemic increase in CXCR2+ neutrophils correlates with 
poor prognosis in PDAC.
 ► CXCR2 blockade, both alone and in combination with 
FOLFIRINOX chemotherapy, prevents TAN mobilisation 
from the peripheral blood and increases effector tumour-
infiltrating T cells in an orthotopic PDAC model.
 ► Myeloid substitution is recapitulated in an orthotopic PDAC 
model, and combining CCR2 plus CXCR2 blockade reduces 
total tumour-infiltrating myeloid cells, enhancing antitumour 
immunity and chemotherapeutic responses compared with 
either therapy alone.
how might it impact on clinical practice in the foreseeable 
future?
Targeting the predominant tumour-infiltrating myeloid lineages 
in combination may represent an optimal approach to reverse 
the immunosuppressive TME and enhance chemotherapeutic 
responses in PDAC.
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day or PF-04136309 (Pfizer) at a dose of 100 mg/kg given SQ 
twice daily. FOLFIRINOX (5-FU (25 mg/kg), irinotecan (50 mg/
kg) and oxaliplatin (5 mg/kg)) was administered intravenously 
weekly. For depletion experiments, 250 µg of Ly6G (A18) or 
CD8 (2.43) antibodies was administered IP every 4 days (BioX-
Cell). Treatment was continued until designated time points, at 
which time mice were euthanised and perfused. Tumours were 
collected along with blood and bone marrow in heparinised 
capillary tubes followed by RBC lysis (BioLegend).
Flow cytometry
Single cell suspensions were assessed for viability with Trypan 
Blue and manually counted, then incubated with Fc receptor 
blocking solution followed by fluorophore-conjugated anti-
bodies (BioLegend). For intracellular staining, cells were 
permeabilised and stained with appropriate antibody per 
manufacturer’s instructions (eBioscience). Flow cytometry was 
performed on an LSRII (BD Biosciences) and analysed using 
FloJo Version X (Tree Star). See online supplementary mate-
rials for list of antibodies.
rnA isolation and PCr
Snap-frozen samples were homogenised in Trizol (Thermo 
Scientific) with a Tissue Lyser LT (Qiagen). Total RNA was 
extracted with the RNeasy Mini Kit and treated with DNase 
(Qiagen). RNA was reverse transcribed into cDNA and quan-
titative real-time PCR performed using TaqMan PCR Master 
Mix and predesigned TaqMan Gene Expression Assays 
(Thermo Scientific). Gene expression was normalised to lycer-
aldehyde-3-phosphate dehydrogenase (GAPDH), hypoxan-
thine phosphoribosyltransferase (HPRT1) and β-actin using 
the comparative CT (ΔΔCT) method.
Immunofluorescence and immunohistochemistry
Five micrometre tumour sections were cut from embedded 
tissue using an HM 325 microtome (Thermo Scientific) and 
baked at 70°C for 30 min. Tissue sections were dewaxed in 
xylene followed by rehydration and antigen retrieval using 
citrate buffer (10 mM sodium citrate, 0.05% Tween 20), then 
washed and blocked with serum-free protein block (DAKO). 
Primary antibodies were diluted in antibody diluent (DAKO) 
and incubated overnight at 4°C then washed and stained with 
fluorescently conjugated secondary antibodies diluted 1:200 
for 30 min at room temperature. For immunohistochemistry, 
endogenous peroxidase activity was blocked by incubation 
with 3% H2O2 in PBS, followed by primary and biotinylated 
secondary antibodies diluted 1:200. Antigen staining with 
VECTASTAIN Standard ABC Kit (Vector Laboratories) 
and Liquid DAB+ Substrate Chromagen System (DAKO) 
was performed, and slides were counterstained with Gill’s 
Hematoxylin (Fisher Scientific). Images were acquired on an 
Olympus BX43 microscope with a DP80 camera and analysed 
with manufacture’s software (Olympus).
statistical analysis
SAS V.9.1 and GraphPad Prism V.4 (GraphPad Software) were 
used for statistical analysis using a significance level of α=0.05. 
A two-sided Student’s t-test or Mann-Whitney test was used 
for normally and non-Gaussian distributed data, respectively. 
Matched samples were compared with a two-sided paired t-test. 
A one-way analysis of variance using the Tukey post-test was 
used for multiple comparisons. Survival analysis was performed 
using the log-rank test.
resulTs
Preoperative nlr correlates with survival following PdAC 
resection
Using standard ROC analysis the optimal NLR cut-off was deter-
mined to be 2.1, with patients (n=439) stratified into high (>2.1) 
and low (≤2.1) cohorts. Overall, a high NLR (n=286) was 
associated with a worse prognosis and 5-year survival of 17.3% 
compared with 26.5% in the low NLR group (n=153) following 
PDAC resection (figure 1A). Patients with a high NLR had a median 
survival of 18 months compared with 23 months in the low NLR 
group (HR=0.74 (95% CI 0.58 to 0.93)). Multiple logistic regres-
sion using baseline patient and tumour characteristics reveals that 
an elevated preoperative NLR is independently associated with a 
shorter mean survival (online supplementary table S1).
neutrophils expressing CXCr2 are elevated in the blood and 
bone marrow of patients with human PdAC
Flow cytometry analysis reveals that neutrophils in both the blood 
and bone marrow express CXCR2 (figure 1B). Patients with 
PDAC demonstrated a significant increase in CXCR2+ neutro-
phils in the blood compared with healthy controls (figure 1C). 
The circulating CXCR2+ neutrophil burden was higher in patients 
surviving less than 1 year and inversely correlated with survival 
(P=0.019; Pearson’s rho=−0.66 (95% CI −0.90 to −0.14)). 
Likewise, patients with PDAC had increased CXCR2+ neutro-
phils in bone marrow compared with controls (figure 1D). Similar 
to the peripheral blood, this increase was associated with worse 
1-year survival and the percentage of bone marrow CXCR2+ 
neutrophils inversely correlated with survival (P=0.014; Pear-
son’s rho=−0.50 (95% CI −0.76 to −0.11)). This indicates that 
PDAC results in a systemic elevation of CXCR2+ neutrophils 
in the blood and bone marrow, correlating with worse clinical 
outcomes.
Increased expression of elr+ chemokines correlates with the 
prevalence of tumour-infiltrating CXCr2+ TAn
Consistent with prior reports, we found that human PDAC 
tumours overexpress GM-CSF and G-CSF, but not M-CSF, relative 
to normal pancreas (figure 2A).24 25 PDAC tumours had increased 
expression of the ELR+ chemokines CXCL1, CXCL2, CXCL5 
and CXCL8 compared with normal tissue (figure 2B). Fluores-
cent microscopy shows neoplastic ductal cells, rather than stromal 
elements, to be the primary source of CXCL1, CXCL2, CXCL5 
and CXCL8 (figure 2C). In particular, we focused on CXCL5 as it 
demonstrated the greatest fold increase in PDAC expression among 
the ELR+ chemokines and found a positive correlation between 
CXCL5 expression and both tumour-infiltrating CD15+ granu-
locytes (Pearson rho=0.837 (95% CI 0.73 to 0.90); figure 2D) 
and neutrophil elastase positive (NE+) granulocytes (Pearson 
rho=0.635 (95% CI 0.43 to 0.70); figure 2E). Overall, this 
suggests that PDAC expression of ELR+ chemokines, in particular 
CXCL5, may be important in facilitating recruitment of CXCR2+ 
neutrophils.
PdAC tumours are infiltrated by CXCr2+ TAn with prognostic 
implications in human disease
Compared with normal pancreas, PDAC is heavily infil-
trated by CXCR2+ TAN (figure 2F). Similar to our finding 
that the NLR was prognostic in the peripheral blood, we 
found PDAC tumours with a low, mid or high CD15+ TAN 
to CD8+ lymphocyte ratio had median survival of 2, 1.5 
and 1 years, respectively (figure 2G). A high ratio was asso-
ciated with worse overall survival compared with both the 
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Figure 1 Systemic elevation of CXCR2+ neutrophils in the peripheral blood and bone marrow correlates with overall survival in patients with human 
PDAC. (A) Standard ROC analysis (P<0.0001; AUC=0.74 (95% CI 0.71 to 0.78)) was used to ascertain the preoperative neutrophil to lymphocyte 
ratio (NLR) optimal cut-off point of 2.1 with a sensitivity of 66.2% (95% CI 61.2 to 70.6) and specificity of 73.2% (95% CI 68.9 to 77.3). All patients 
(n=439) were stratified into high (>2.1; n=286) and low (≤2.1; n=153) cohorts and a Kaplan-Meier survival analysis following PDAC resection was 
performed, with alive patients censored at date of last follow-up. (B) Representative flow cytometry plots gated on CD45+ cells depicting CD15+, 
CXCR2+ neutrophils in the peripheral blood (top) and bone marrow (bottom) from healthy controls (left) and patients with PDAC (right). (C) Analysis 
of CXCR2+ neutrophils in the peripheral blood of healthy controls (n=6) and patients with PDAC (n=17) represented as a percentage of total cells 
(left). Comparison of CXCR2+ neutrophils in the peripheral blood of patients with human PDAC surviving (n=11) or deceased (n=6) at 1 year following 
surgical resection (middle). Pearson correlation (two tailed) of peripheral blood CXCR2+ neutrophils and survival following surgical resection (right). 
(D) Analysis of CXCR2+ neutrophils in the bone marrow of healthy controls (n=5) and patients PDAC (n=24) represented as a percentage of total 
cells (left). Comparison of CXCR2+ neutrophils in the bone marrow of patients with human PDAC surviving (n=18) or deceased (n=6) at 1 year 
following surgical resection (middle). Pearson correlation (two tailed) of bone marrow CXCR2+ neutrophils and survival following surgical resections 
(right). Two-sided Mann-Whitney test was used to determine P values for comparisons between groups. AUC, area under the curve; PDAC, pancreatic 
adenocarcinoma; ROC, receiver operator curve.
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Figure 2 Elevated ELR+ chemokine expression correlates with CXCR2+TAN and worse prognosis in human PDAC. (A) Quantitative real-time PCR 
analysis of GM-CSF, M-CSF and G-CSF expression from human PDAC tumours (n=11) relative to normal pancreas (n=7). (B) Quantitative real-time 
PCR analysis of the ELR+ chemokine CXCL1, CXCL2, CXCL5 and CXCL8 expression from human PDAC tumours (n=11) relative to normal pancreas 
(n=7). (C) Fluorescent microscopy images demonstrating CXCL1, CXCL2, CXCL5 and CXCL8 (red) expression with DAPI nuclear (blue) and cytokeratin 
7 (CK7; green) counterstain in human PDAC tumours. (D) Pearson (two tailed) correlation of CXCL5 expression intensity and CD15+ TAN infiltrate 
in human PDAC tumours (n=54). (E) Pearson correlation (two tailed) of CXCL5 expression intensity and NE+ TAN infiltrate in human PDAC tumours 
(n=54). (F) Representative immunofluorescence showing CD11b+, CD15+ TAN (yellow) in normal pancreas (top) and PDAC tumours (bottom). 
Representative flow cytometry plots illustrating CD11b+, CD15+, CD66b+, CXCR2+ TAN in normal pancreas (top) and PDAC tumour (bottom) gated 
on CD45+ cells. Graph depicts CXCR2+ TAN as percentage of total cells by flow cytometry from normal pancreas (n=7) and human PDAC tumours 
(n=11). (G) Survival analysis of intratumoural CD15+ to CD8+ ratio from resected human PDAC tumour microarray (n=49). (H) Survival analysis of 
intratumoural NE+ to CD8+ ratio from resected human PDAC tissue microarray (n=49). (I) Survival analysis of intratumoural CXCL5 to CD8+ ratio 
from resected human PDAC tissue microarray (n=49). Two-tailed unpaired t-test or Kaplan-Meier survival analysis was used to calculate P values. 
*P<0.05; **P<0.01; ***P<0.001. G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; M-CSF, 
macrophage colony-stimulating factor; PDAC, pancreatic adenocarcinoma; TAN, tumour-associated neutrophils.
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mid (P=0.009; HR=0.44 (95% CI 0.14 to 0.76)) and low 
(P=0.006; HR=0.35 (95% CI 0.12 to 0.70)) groups. Further-
more, PDAC patients with a high NE to CD8 intratumoural 
ratio demonstrated decreased survival compared with those in 
either the mid (P=0.008; HR=0.35 (95% CI 0.07 to 0.51)) 
or high (P=0.006; HR=0.34 (95% CI 0.10 to 0.68)) cohorts 
(figure 2H). Consistent with our finding that CXCL5 expres-
sion correlated with TAN infiltrate, an elevated CXCL5 to 
CD8+ intratumoural ratio was also associated with a worse 
prognosis, with a median survival of 0.65 years compared with 
the 1.3 years (P=0.019; HR=0.39 (95% CI 0.05 to 0.75)) 
or 1.8 years (p=0.005; HR=0.47 (95% CI 0.03 to 0.51)) 
observed in the mid and low groups, respectively (figure 2I). In 
summary, this suggests that the CXCR2+ TAN are a predomi-
nant immune infiltrate and have clinical significance in PDAC.
CXCr2 inhibition sequesters neutrophils in the blood and 
prevents TAn accumulation in orthotopic PdAC tumours
Orthotopically implanted, syngenic KCKO pancreatic tumours 
demonstrated increased expression of GM-CSF, G-CSF and the 
CXCR2 ligands CXCL1, CXCL2 and CXCL5 relative to normal 
pancreas (figure 3A and figure 3B). In addition, we found a systemic 
elevation of CXCR2+ neutrophils in the bone marrow and periph-
eral blood of tumour-bearing mice relative to controls (figure 3C). 
CXCR2i treatment increased the absolute number of neutrophils 
in the periphery, but not the bone marrow, compared with vehicle 
treated animals. In addition, we explored the impact of FOLF-
IRINOX, which also demonstrated an increase in circulating, but 
not bone marrow, granulocytes following CXCR2i plus myelosup-
pressive chemotherapy (online supplementary figure S2).
The primary tumour was characterised by an abundant 
infiltrate of polynuclear Ly6G+ cells, which was abrogated 
with CXCR2 inhibition (figure 3D). Targeting CXCR2+ TAN 
resulted in a significant reduction in subcutaneous KCKO 
tumour progression (figure 3E). To confirm these findings, we 
examined orthotopic tumours from another syngenic PDAC cell 
line derived from the KPC genetically engineered model (p48-
CRE/LSL-KrasG12D/p53flox/flox), revealing CXCR2i also prevented 
TAN accumulation in this model (online supplementary figure 
S3). Furthermore, treatment with either CXCR2i or a Ly6G-spe-
cific depleting antibody (A18) demonstrated a similar reduction 
in established KPC disease burden compared with controls 
(figure 3F). Collectively, this suggests that CXCR2 blockade 
prevents neutrophil trafficking from the blood, reducing TAN 
with similar therapeutic efficacy to systemic depletion.
Targeting a myeloid subset results in tumour compensatory 
recruitment of alternative bone marrow-derived cell 
populations
Neutrophil substitution for CCR2+ TAM has been observed 
in tumour models, and targeting CCR2 has shown promising 
results in a clinical trial treating borderline resectable and locally 
advanced PDAC.19–21 Thus, we examined if CXCR2+ TAN 
compensation occurred in human patients by analysing base-
line and post-treatment tumour biopsies following 4 weeks of 
treatment with CCR2i, which revealed a significant increase 
in CXCR2+ TAN following CCR2 blockade (figure 4A). Both 
tumour-bearing CCR2−/− and CCR2i-treated wild-type mice 
demonstrated a compensatory replacement of TAM by CXCR2+ 
granulocytes, which also occurred when treated in combina-
tion with FOLFIRINOX (figure 4B,C). Conversely, depletion 
of Ly6G+ neutrophils has been reported to result in elevated 
TAM in a spontaneous PDAC murine model, which is similar 
to our findings following CXCR2i treatment (figure 4C,D)
(figure 4D).12 One possible explanation for this phenomenon 
is the observation that factors associated with TAM produc-
tion and recruitment, namely CSF1 and CCL2, were increased 
following blockade of CXCR2+ TAN. Similarly, CCR2i resulted 
in an increased expression of CXCL1, CXCL2 and CXLC5 as 
well as G-CSF (online supplementary figure S4). Nonetheless, 
combined CCR2i plus CXCR2i treatment, both alone and in 
combination with FOLFIRINOX, prevented this compensatory 
effect and reduced tumour-infiltrating myeloid cells (figure 4E).
Combined CCr2 plus CXCr2 blockade enhances 
chemotherapeutic efficacy and improves survival in tumour-
bearing mice
While CCR2i and CXCR2i were effective at reducing established 
orthotopic tumour burden as single agents, using a dual CCR2 
plus CXCR2 blockade strategy resulted in significantly smaller 
KCKO tumours (figure 4F). Furthermore, this reduction in tumour 
burden was enhanced when myeloid blockade was combined with 
FOLFIRINOX. Administration of PF-04136309, a small mole-
cule CCR2i used in a human PDAC clinical trial, in combination 
with FOLFIRINOX, reveals that chemotherapy increased survival 
compared with vehicle treatment (P<0.001; median survival: 15 
vs 19 days), but the addition of either CCR2i (P=0.013; median 
survival: 19 vs 25 days) or CXCR2i (P=0.013; median survival: 
19 vs 24 days) further improved survival in mice with orthotopic 
tumours derived from the KPC genetically engineered model 
(figure 4G). Furthermore, dual CCR2 plus CXCR2 blockade with 
FOLFIRINOX increased survival compared with either CCR2i 
(P=0.016; median survival: 25 vs 33 days) or CXCR2i (P=0.015; 
median survival: 24 vs 33 days). Overall, this suggests that 
targeting myeloid cell recruitment with both CCR2 and CXCR2 
simultaneously enhances chemotherapeutic responses compared 
with either strategy used alone.
reduction of tumour-infiltrating myeloids increases effector 
T cells in PdAC-bearing mice
Targeting CCR2+ TAM and CXCR2+ TAN in combination 
resulted in a significantly greater influx of both CD8+ and CD4+ 
TIL compared with either strategy alone, which was also found 
when tested in combination with FOLFIRINOX (figure 5A,B). 
Examination of TIL subsets found that myeloid-targeting strat-
egies decreased immunosuppressive FoxP3+ and CD25+ regula-
tory T cell infiltrate, with no further clear benefit found when 
CCR2i and CXCR2i were combined (figure 5C). Confirming 
our prior findings, fluorescent microscopy shows that CD8+ TIL 
are increased following myeloid blockade (online supplemen-
tary figure S5). Next, we assessed markers of CD8+ TIL acti-
vation status, which revealed an increase in intracellular IFNγ 
and CD44+, CD69+, CD62L− surface marker expression on 
CD8+ TIL following combined CCR2i plus CXCR2i treatment 
(figure 5D,E). To confirm that this increase in activation status 
faithfully reflected antigen recognition by the T cell receptor 
(TCR), we next examined the green fluorescent protein (GFP) 
expression in CD8+ lymphocytes extracted from PDAC tumours 
in Nur77GFP reporter mice, which upregulate GFP in response 
to TCR stimulation.26 27 This demonstrated an increase in GFP 
expressing CD8+ TIL following dual CCR2i plus CXCR2i 
treatment (figure 5F). Overall, these results indicate that the 
corresponding reduction of tumour-infiltrating myeloid cells 
and influx of effector TIL following dual chemokine receptor 
inhibition may represent the ideal treatment strategy to augment 
chemotherapeutic responses in PDAC.
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Figure 3 Targeting CXCR2 sequesters neutrophils in the peripheral blood and prevents TAN accumulation in PDAC tumour-bearing animals. (A) 
Quantitative real-time PCR was performed for expression of GM-CSF, M-CSF and G-CSF on normal murine pancreas (n=5) and orthotopically 
implanted KCKO PDAC tumours (n=9). (B) Quantitative real-time PCR was performed for expression of ƩCXC+ chemokines on normal murine 
pancreas (n=5) and orthotopically implanted PDAC tumours (n=9). (C) Representative flow cytometry plots of CXCR2+ neutrophils in the peripheral 
blood (top) and bone marrow (bottom) from non-tumour controls and tumour-bearing animals receiving treatment with vehicle or CXCR2i. 
Graphs depict absolute number of CXCR2+ neutrophils (×105) per 100 µL of blood (n=9–12 per group) and bone marrow from the femur (n=4 per 
group) of non-tumour-bearing controls and KCKO tumour-bearing animals receiving treatment with vehicle or CXCR2i (D) Representative IHC and 
analysis of Ly6G+ TAN from orthotopic PDAC tumours of animals treated with vehicle or CXCR2i (n=6–9 per group). (E) Tumour growth curve of 
subcutaneously implanted KCKO tumours from mice treated with vehicle or CXCR2i. Treatment initiated following randomisation of palpable tumours 
on postimplantation day 10. (F) Tumour weights from established orthotopic KPC tumours treated with CXCR2i or Ly6G specific depleting antibody 
for 20 days (n=6 per group). Data reflect analysis from at least two repeated experiments. Two-tailed unpaired t-test or ANOVA was used to calculate 
P values. *P<0.05; **P<0.01; ***P<0.001. ANOVA, analysis of variance; PDAC, pancreatic adenocarcinoma; TAN, tumour-associated neutrophils.
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Figure 4 Human and murine PDAC tumours demonstrate myeloid substitution following bone marrow cell targeted therapies, which is overcome 
by combined CCR2 plus CXCR2 blockade. (A) Comparison total PDAC-infiltrating CXCR2+ TAN was assessed by flow cytometry from matched FNA 
tumour biopsies at baseline following treatment with an orally dosed, small molecule CCR2i (blue) in combination with FOLFIRINOX (n=6 matched 
specimens). (B) Absolute number of CXCR2+ TAN per gram of tissue (×105) was assessed by flow cytometry from CCR2−/− and wild-type mice 
treated with vehicle alone (left) or in combination with FOLFIRINOX (right) 25 days following orthotopic KCKO tumour implantation (n=5–6 mice/
group). (C) Absolute number of CXCR2+ TAN (Left) and CCR2+ TAM (Right) per gram of tumour (×105) was assessed by flow cytometry following 
25 days of treatment with chemokine blockade alone (n=12 mice/group) . (D) Absolute number of CXCR2+ TAN (Right) and CCR2+ TAM (Left) per 
gram of tumour (×105) was assessed by flow cytometry following 25 days of treatment with chemokine blockade in combination with FOLFIRINOX 
chemotherapy (n=9 mice/group). (E) Total tumour-infiltrating myeloids was assessed by flow cytometry and represented as percentage change from 
vehicle treated controls following chemokine receptor blockade alone and in combination with FOLFIRINOX (n=9–12 mice/group). (F) Orthotopic 
KCKO tumour weights following 25 days of treatment with chemokine receptor blockade alone (left; n=12 mice/group) and in combination with 
FOLFIRINOX chemotherapy (right; n=9 mice/group). (G) Survival analysis of KPC orthotopic tumour-bearing mice treated with FOLFIRINOX alone and 
in combination with PF-04136309 (CCR2i) or CXCR2i (n=10–15 mice per group). One-way ANOVA and two-tailed paired, for matched samples, or 
unpaired t-test were used to calculate P values. For survival analysis, P values were obtained by the log-rank (Mantel-Cox) test. *P<0.05; **P<0.01; 
***P<0.001. ANOVA, analysis of variance; PDAC, pancreatic adenocarcinoma; TAM, tumour-associated macrophages; TAN, tumour-associated 
neutrophils.
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dual CCr2 plus CXCr2 blockade restores antitumour 
immunity in established PdAC tumours
The effector to suppressor cell ratio in established, orthotopically 
implanted PDAC tumours was increased following treatment with 
either CCR2i or CXCR2i compared with controls (figure 5G). 
Nonetheless, simultaneous targeting of both CCR2+ TAM and 
CXCR2+ TAN further enhanced this effect, which was magnified 
when combined with FOLFIRINOX. This corresponded with 
reduced expression of immunosuppressive genes and increase in 
factors associated with antitumour immunity and cytolytic T cell 
responses (figure 5H). As our results suggest that antitumour 
activity following myeloid blockade is mediated through an adap-
tive immune mechanism, we performed CD8 depletion studies that 
showed the therapeutic efficacy of myeloid blockade is lost in the 
Figure 5 Depleting PDAC-infiltrating CCR2+ macrophages and CXCR2+ neutrophils in combination improves antitumour T cell responses. (A) 
Absolute number of CD8+ TIL per gram of tumour (×105) was assessed by flow cytometry from orthotopically implanted KCKO tumours following 
25 days of treatment with chemokine blockade alone (left; n=12 mice/group) and in combination with FOLFIRINOX chemotherapy (right; n=9 mice/
group). (B) Absolute number of CD4+ TIL per gram of tumour (×105) was assessed by flow cytometry from orthotopically implanted KCKO tumours 
following 25 days of treatment with chemokine blockade alone (left; n=12 mice/group) and in combination with FOLFIRINOX chemotherapy 
(right; n=9 mice/group). (C) Regulatory T cells (FoxP3+  and CD25+) expressed as percentage of total CD4+ TIL was assessed by flow cytometry 
from orthotopically implanted KCKO tumours following 25 days of treatment with chemokine blockade alone (left; n=9–12 mice/group) and in 
combination with FOLFIRINOX chemotherapy (right; n=6 mice/group). (D) Intracellular IFNγ-positive CD8+ TIL expressed as percentage of total CD8+ 
T cells was assessed by flow cytometry from orthotopically implanted KCKO tumours following 25 days of treatment with chemokine blockade alone 
(left; n=6 mice/group) and in combination with FOLFIRINOX chemotherapy (right; n=6 mice/group). (E) CD69+, CD44+, CD62L−and activated CD8+ 
TIL expressed as percentage of total CD8+ TIL were assessed by flow cytometry from orthotopically implanted KCKO tumours following 25 days of 
treatment with chemokine blockade alone (left; n=9 mice/group) and in combination with FOLFIRINOX chemotherapy (right; n=6 mice/group). (F) GFP 
expressing CD8+ TIL assessed by flow cytometry from Nur77GFP T cell report mice with KCKO tumours 21 days following treatment with chemokine 
receptor inhibitor (n=4–6 mice/group). (G) Intratumoural effector to suppressor cell ratio per gram of tumour from orthotopically implanted 
KCKO tumours following 25 days of treatment with chemokine blockade alone (left; n=9–12 mice/group) and in combination with FOLFIRINOX 
chemotherapy (right; n=9 mice/group). (H) Orthotopic KCKO tumour gene expression following 25 days of treatment with chemokine blockade alone 
(left; n=5 mice/group) and in combination with FOLFIRINOX chemotherapy (right; n=5 mice/group). (I) Orthotopic KCKO tumour weights following 
chemokine receptor inhibitor with CD8 depleting antibody or IgG control (n=5–6 mice/group). One-way ANOVA was used to calculate P values. 
*P<0.05; **P<0.01; ***P<0.001. ANOVA, analysis of variance; PDAC, pancreatic adenocarcinoma; TIL, tumour- infiltrating lymphocytes. 
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absence of CD8+ lymphocytes (figure 5I). In summary, these data 
highlight the critical importance of bone marrow-derived cells in 
mediating PDAC immune evasion and provides a clinical rationale 
for concurrent targeting of both CCR2+ TAM and CXCR2+ TAN.
dIsCussIOn
Herein we demonstrate that myeloid dynamics within the TME 
facilitates a compensatory increase in an alternative subset of bone 
marrow-derived cells following isolated depletion of either CCR2+ 
TAM or CXCR2+ TAN. Furthermore, we provide the first evidence 
of this phenomenon occurring in human cancer, with post-treatment 
tumour biopsies from patients with non-metastatic PDAC receiving 
a small molecule CCR2i plus FOLFIRINOX demonstrating a 
significant increase in TAN compared with matched baseline 
samples. This increase may have clinical implications as we found 
that CXCR2+ neutrophils are elevated in the blood, bone marrow 
and tumour of patients with human PDAC and correlates with poor 
overall survival. Likewise, tumour-bearing mice demonstrate an 
increase in CXCR2+ neutrophils following therapeutic targeting of 
CCR2+ TAM. Conversely, we also show that preventing CXCR2+ 
neutrophil mobilisation in PDAC results in an increase in TAM, 
and synergistic targeting of both CXCR2+ TAN and CCR2+ TAM 
improves antitumour immunity and reduces established tumour 
burden compared with either therapy alone. In summary, these 
data build on emerging therapies targeting myeloid cells in human 
cancer and suggests that targeting both TAN and TAM collectively 
may present the optimal therapeutic combination in combating the 
immunosuppressive microenvironment.
An emerging body of evidence supports the role of TAN in 
facilitating tumour immune evasion and progression.28 Patients 
with cancer demonstrate a systemic increase in neutrophils, and 
the NLR is a biomarker in several tumours, including PDAC, and 
elevated neutrophils in the circulation correlated with tumour-in-
filtrating TAN in patients with glioblastoma.29–33 Recruitment of 
CXCR2+ neutrophils via tumour production of ELR+ chemo-
kines has been observed in multiple cancers, with CXCL5 
correlating with increased TAN infiltrate and worse prognosis 
in hepatocellular carcinoma and PDAC.8 9 34 Orally dosed small 
molecule inhibitors of CXCR2 are currently in clinical develop-
ment, with trials demonstrating evidence of target engagement 
and a favourable toxicity profile in non-malignant conditions, and 
targeting CXCR2+ TAN has demonstrated efficacy in preclin-
ical tumour models.35 36 Jamieson et al found CXCR2 blockade 
prevented TAN migration to colorectal tumours and increased 
CD8+ effector TIL, reducing tumour progression. In rhabdomyo-
sarcoma, Highfill et al found that CXCR2 blockade potentiated 
anti-PD1 immunotherapy in tumour-bearing mice.10 13 In pancre-
atic cancer, Stromnes et al12 reported that TAN depletion with a 
Ly6G-specific antibody leads to enhanced CD8+ TIL influx and 
an increase in cancer cell apoptosis in KPC mice. Likewise, strat-
egies using CXCR2 blockade have also been associated with an 
influx of TIL and augmented checkpoint therapy in PDAC.9 11 
Collectively, both our work and that of others strongly suggests 
that targeting CXCR2-mediated mobilisation of neutrophils may 
present a promising therapy for cancer.
Immunosuppressive TAM are also abundant in cancer and 
correlate with poor prognosis.37 Strategies targeting TAM, including 
CCR2 and CSF1 receptor blockade, repolarise the immunosup-
pressive microenvironment, improve responses to chemotherapy 
and reduce metastasis in preclinical models.14 16–18 38 The transla-
tion of these therapies to the clinic has also demonstrated promise 
with our group previously reporting that PF-04136309, an orally 
dosed CCR2i, in combination with FOLFIRINOX, demonstrated 
a favourable clinical response rate compared with chemotherapy 
alone in patients with borderline resectable and locally advanced 
PDAC.19 Correlative studies from this clinical trial showed CCR2i 
reduced TAM and increased TIL, suggesting that CCR2 blockade 
favourably reprogrammes the immunosuppressive TME. Based on 
these findings, larger clinical trials exploring CCR2 blockade in 
metastatic PDAC in combination with gemcitabine plus nab-pacl-
itaxel (NCT02732938) and FOLFIRINOX (NCT02345408) are 
currently in progress. Likewise, strategies targeting CSF1 receptor 
have shown evidence of TAM reduction and promising response 
rates in patients with tenosynovial giant cell tumours, suggesting 
such strategies may be beneficial in the treatment of a variety of 
human cancers.39 40
While TAM targeted therapeutics have demonstrated evidence 
of safety and tolerability in cancer, inhibition of neutrophil 
recruitment has been met with more resistance, particularly 
in combination with chemotherapy regimens associated with 
myelosuppression and neutropaenia. Yet, systemic neutrophilia 
correlates with poor clinical outcomes in cancer, with evidence 
that chemotherapy-induced neutropaenia is protective in multiple 
solid tumours.41–43 Furthermore, elevated neutrophils have been 
associated with resistance to conventional therapies.44 45 Kuri-
hara et al46 reported similar findings in advanced PDAC, where 
neutropaenia conveyed a survival benefit following gemcitabine 
treatment. Importantly, a study in ovarian cancer found the base-
line neutrophil count to correlate with survival, but carboplatin 
dose-escalation based on nadir neutrophil counts did not improve 
clinical outcomes, suggesting that chemotherapy does not over-
come tumour-mediated granulocyte expansion.47 We used the 
FOLFIRINOX regimen in this study as it has shown an improve-
ment in survival in PDAC compared with gemcitabine but is asso-
ciated with an increase in treatment-related toxicities, including 
neutropaenia.48 Our results indicate that conventional chemo-
therapy does not sufficiently target TAN and suggests that CXCR2 
inhibition may represent a synergistic treatment combination.
Despite successes targeting a single myeloid subset, the 
dynamics of bone marrow-derived cell recruitment in response to 
such immunomodulatory strategies has not been fully evaluated. 
Sawanobori et al21 revealed that CCR2−/− mice had an influx of 
tumour-infiltrating neutrophils in both Lewis lung carcinoma and 
B16 melanoma tumours. Pahler et al20 have reported similar find-
ings in cervical cancers from CCR2−/− mice, in which the neutro-
phil influx was responsible for treatment resistance. Neutrophil 
substitution for macrophages has also been reported to other sites 
of inflammation in CCR2−/− mice infected with Listeria monocy-
togenes or viral-induced arthritis.49 50 Conversely, there is evidence 
that neutrophil depletion results in a compensatory increase in 
TAM. Stromnes et al showed that targeted depletion of neutrophils 
resulted in a systemic accumulation of myelomonocytic cells in 
both the periphery and tumour in a genetically engineered model 
of PDAC, suggesting that tumour-infiltrating myeloid compen-
sation may occur following therapies targeting TAN as well.12 
Collectively, these findings demonstrate both the critical nature of 
tumour-mediated recruitment of bone marrow-derived cells and 
support the concept of tumour-infiltrating myeloid substitution 
to counteract therapeutic strategies targeting an isolated myeloid 
cell population. Thus, further understanding of the mechanisms 
behind this phenomenon and how it may contribute to treatment 
resistance is paramount in the clinical application of targeting 
myeloid cells in cancer.
The dynamic communication between the tumour and bone 
marrow demonstrates the importance of precisely defining 
the immune composition of the TME and recognition of 
the potential mechanisms that tumours may use to combat 
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immunomodulatory therapies. Future studies should expand 
beyond the current isolation of selective targeting of either 
TAM or TAN and progress to multimodality strategies aimed 
at elucidating the complex interactions among all inflammatory 
cells within the TME. Importantly, the ability of tumours to 
recruit additional myeloid populations should be considered as a 
complementary target to enhance antitumour therapies.
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